Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Bio-Gene TechnologyASX:BGT -5.00% 3-Year EBITDA Growth Rate is 7.60% as of Dec. 2025, which is 300% above its 10-year median of 1.90. The stock has 2 warning signs investors should review. Among 1,130 Biotechnology companies, Bio-Gene Technology ranks worse than 58.76% on this metric.
During the past 3 years, the average EBITDA Per Share Growth Rate was 7.60% per year.
During the past 5 years, the average EBITDA Per Share Growth Rate was 3.10% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 8 years, the highest 3-Year average EBITDA Per Share Growth Rate of Bio-Gene Technology was 13.70% per year. The lowest was -1.80% per year. And the median was 1.90% per year.
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
Bio-Gene Technology 3-Year EBITDA Growth Rate Related Terms
ASX:BGT vs VRTX, REGN, RVMD: 3-Year EBITDA Growth Rate Comparison
For the Biotechnology subindustry, Bio-Gene Technology's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Bio-Gene Technology 3-Year EBITDA Growth Rate vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Bio-Gene Technology's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where Bio-Gene Technology's 3-Year EBITDA Growth Rate falls into.
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of 7.60% mean?
Bio-Gene Technology (ASX:BGT) has a 3-Year EBITDA Growth Rate of 7.60% as of Dec. 2025. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Bio-Gene Technology and its competitors. This is 300% above median its historical median of 1.90. According to the industry distribution chart, Bio-Gene Technology ranks #664 out of 1130 companies in the Biotechnology industry, placing it in the top 58.8%.
Is Bio-Gene Technology's 3-Year EBITDA Growth Rate too high?
Bio-Gene Technology's current 3-Year EBITDA Growth Rate of 7.60% is 300% above median its 10-year median of 1.90. The Biotechnology industry median 3-Year EBITDA Growth Rate is 14.85. Bio-Gene Technology's value of 7.60% is 48.8% below this industry median. Based on the distribution chart, Bio-Gene Technology ranks #664 out of 1130 companies in the Biotechnology industry, which is below the industry midpoint.
How does Bio-Gene Technology's 3-Year EBITDA Growth Rate compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Bio-Gene Technology ranks #664 out of 1130 companies for 3-Year EBITDA Growth Rate. This places Bio-Gene Technology in the lower half of its industry. The industry median 3-Year EBITDA Growth Rate is 14.85. Bio-Gene Technology's value of 7.60% is 48.8% below this benchmark. While the company's 10-year median is 1.90 vs. the industry median of 14.85, Bio-Gene Technology has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Biotechnology company?
The median 3-Year EBITDA Growth Rate among Biotechnology companies is 14.85, based on 1,130 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Bio-Gene Technology's current 3-Year EBITDA Growth Rate of 7.60% is 48.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Bio-Gene Technology and its competitors. For the Biotechnology industry, the median 3-Year EBITDA Growth Rate is 14.85 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Bio-Gene Technology's current 3-Year EBITDA Growth Rate is 7.60%, which is 300% above median its own 10-year median of 1.90. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bio-Gene Technology stock overvalued right now?
Bio-Gene Technology (ASX:BGT) has a current 3-Year EBITDA Growth Rate of 7.60%. The current 3-Year EBITDA Growth Rate is 7.60%, which is 300% above median its 10-year median of 1.90 and 48.8% below the Biotechnology industry median of 14.85. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For Bio-Gene Technology (ASX:BGT), the current 3-Year EBITDA Growth Rate is 7.60% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Bio-Gene Technology Ltd is an Australian company developing novel bio-insecticides to address the challenges of insecticide resistance and toxicity. Its products are based on a naturally occurring class of compounds to overcome resistance to control pests with minimal impact on human health and the environment. Bio-Gene's products have multiple applications across public health, crop protection, grain storage, and consumer use. The company operates in one business segment, being the conduct of research and development activities in the discovery of novel insecticides.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:BGT has been successfully added to your 
